Cargando…
Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting
BACKGROUND: Current strategies for risk stratification of patients with acute myeloid leukemia assign approximately 40% of patients to the intermediate-risk group, where uncertainty about optimal therapy still persists. OBJECTIVE: The objective of this study was to assess the cost effectiveness of a...
Autores principales: | Tremblay, Gabriel, Rousseau, Ben, Marquis, Miriam, Beaubois, Cyrielle, Sauvageau, Guy, Hébert, Josée |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885508/ https://www.ncbi.nlm.nih.gov/pubmed/31392669 http://dx.doi.org/10.1007/s40258-019-00503-5 |
Ejemplares similares
-
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
por: Marquis, Miriam, et al.
Publicado: (2018) -
Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
por: Marquis, Miriam, et al.
Publicado: (2019) -
Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia
por: Lisi, Véronique, et al.
Publicado: (2022) -
HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition
por: Moison, Céline, et al.
Publicado: (2022) -
A role for GPx3 in activity of normal and leukemia stem cells
por: Herault, Olivier, et al.
Publicado: (2012)